



Tafinlar in Jordan

The JFDA named-patient coordination pathway — indicative 2026

ONCOLOGY · BRAF-MUTANT CANCERS

The clinical situation

Tafinlar (dabrafenib) is an FDA-approved oral selective BRAF kinase inhibitor dosed 150 mg twice daily in combination with trametinib for BRAF V600-mutant unresectable or metastatic melanoma, adjuvant melanoma, metastatic NSCLC, anaplastic thyroid cancer, and solid tumours with BRAF V600E mutation. Manufactured by Novartis. Requires documented BRAF V600 mutation testing and coordinated combination-therapy initiation.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating oncologist confirms BRAF V600 mutation status and documents a written clinical rationale and prior line history.
- 2 Treatment facility confirmed.** A Jordanian oncology centre (Amman or Irbid tertiary facility such as King Hussein Cancer Center) accepts the case and sets the combination-therapy plan.
- 3 JFDA named-patient application.** Clinical rationale, patient reference, product details, and chain-of-custody plan are filed with the Jordan Food & Drug Administration.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner, booked to your initiation date.
- 5 Arrival & administration.** The facility receives the product and initiates under your oncologist's care; ongoing cycles dispensed per the combination protocol.

Indicative economics

Reference US cash-pay range: USD 12,000–14,000 per 30-day supply. Combination partner (trametinib), JFDA documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete JFDA application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and JFDA review. **Logistics.** Temperature-monitored shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating oncologist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Tafenlar × Jordan first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/tafinlar-jordan.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team